ICER Issues Draft Evidence Report for Assessment of Trikafta

The Institute for Clinical and Economic Review (ICER) recently posted a draft evidence report to outline their initial assessment of the clinical effectiveness and value of CFTR modulators, including elexacaftor/tezacaftor/ivacaftor (TrikaftaTM). The document is open for public comment through March 18.


Feb. 20, 2020 | 2 min read

On February 20, the Institute for Clinical and Economic Review (ICER) posted a draft evidence report on their assessment of cystic fibrosis therapies. This follows ICER's announcement in early September 2019 that they would be reviewing three cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including elexacaftor/tezacaftor/ivacaftor (TrikaftaTM), the triple-combination therapy approved by the U.S. Food and Drug Administration (FDA) in October 2019.

CFTR modulators are critically important medicines that have the power to transform the lives of many people living with CF.

The CF Foundation will provide feedback to ICER on the draft evidence report to help ensure their final assessment reflects the complexities of CF and the importance of CFTR modulators.

ICER is inviting people from the CF community to provide public comment on the draft evidence report to help inform the final report. The input period runs through March 18. Comments can be submitted by email to

The final report on CFTR modulators will be released in May 2020.

Read more about this review and ICER's previous reviews on CFTR modulators.

Share this article
CFTR Modulators
Recent news
Cystic Fibrosis Community Perspectives Influence Future of CF Care Model
News | 4 min read
CF Foundation Adapts Registry Reporting to New Race-Neutral Standards
News | 5 min read
Nearly 350 Advocates Urge Congressional Action During 17th Annual March on the Hill
News | 3 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.